NCT03293563 UroCCR Database: French Research Network for Kidney Cancer -UroCCR
| NCT ID | NCT03293563 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Kidney Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 30,000 participants |
| Start Date | 2011-12 |
| Primary Completion | 2040-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30,000 participants in total. It began in 2011-12 with a primary completion date of 2040-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Kidney cancer management has become increasingly complex with the diversification of treatment options and the integration of multidisciplinary care. To meet these challenges, the UroCCR network was established in France as a national registry and research platform dedicated to renal cancer. Funded by the French National Cancer Institute (INCa), UroCCR prospectively collects comprehensive real-world data on patient care and disease evolution, while systematically linking these records with annotated biological samples (plasma, urine, and both healthy and tumour tissues). For each case, more than one thousand variables may be recorded, covering clinical, imaging, and patient-reported information. More than a registry, UroCCR is a collaborative network of clinical and research professionals using a shared, evolving tool that supports rapid implementation of studies and fosters active knowledge generation. Unlike retrospective registries or sample-centred biobanks, UroCCR offers prospective, patient-focused inclusion and a wide scope of investigation-from translational and technological research to clinical evaluation and social sciences. It also supports multiple ancillary studies, including retrospective analyses and prospective clinical or observational trials, and operates under a structured governance system with recognised national and international labels. By combining a rigorously structured, multicentre dataset with linkage to the French national health data system (SNDS), the platform uniquely unites detailed clinical annotation with population-wide coverage, creating a high-value environment for advancing kidney cancer research and care.
Eligibility Criteria
Inclusion Criteria: * Adult patient with kidney cancer * Patient with no opposition to collection of its data for the study Exclusion Criteria: none
Contact & Investigator
Jean-Christophe BERNHARD, PHU
PRINCIPAL INVESTIGATOR
University Hospital, Bordeaux
Frequently Asked Questions
Who can join the NCT03293563 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Kidney Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03293563 currently recruiting?
Yes, NCT03293563 is actively recruiting participants. Contact the research team at jean-christophe.bernhard@chu-bordeaux.fr for enrollment information.
Where is the NCT03293563 trial being conducted?
This trial is being conducted at Brussels, Belgium, Angers, France, Bordeaux, France, Bordeaux, France and 11 additional locations.
Who is sponsoring the NCT03293563 clinical trial?
NCT03293563 is sponsored by University Hospital, Bordeaux. The principal investigator is Jean-Christophe BERNHARD, PHU at University Hospital, Bordeaux. The trial plans to enroll 30,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.